Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma

αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma

(2013) Xiao-Yong Huang et al.   HEPATOLOGY

Identification of transcription factors associated with castration-resistance: Is the serum responsive factor a potential therapeutic target?

(2013) Maria Prencipe et al.   PROSTATE

Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth

(2012) Hannah van Malenstein et al.   CANCER LETTERS

Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma

(2012) Hashem B. El-Serag   GASTROENTEROLOGY

Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update

(2012) Angela Gauthier et al.   HEPATOLOGY RESEARCH

FGFR-4 Arg388 Enhances Prostate Cancer Progression via Extracellular Signal-Related Kinase and Serum Response Factor Signaling

(2011) W. Yu et al.   CLINICAL CANCER RESEARCH

Sorafenib Inhibits the Hepatocyte Growth Factor-Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma

(2011) T. Nagai et al.   MOLECULAR CANCER THERAPEUTICS

Serum response factor depletion affects the proliferation of the hepatocellular carcinoma cells HepG2 and JHH6

(2010) Rossella Farra et al.   BIOCHIMIE

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Expression and Prognostic Significance of Serum Response Factor in Cholangiocarcinoma

(2010) Shin Young Park et al.   Korean Journal of Pathology

Role of serum response factor in the pathogenesis of disease

(2010) Joseph M Miano   LABORATORY INVESTIGATION

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

(2010) A Singh et al.   ONCOGENE

Serum response factor: Look into the gut

(2010) Cristina Modak   WORLD JOURNAL OF GASTROENTEROLOGY

Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway

(2009) Z. Wang et al.   CANCER RESEARCH

MicroRNA-122 Inhibits Tumorigenic Properties of Hepatocellular Carcinoma Cells and Sensitizes These Cells to Sorafenib

(2009) Shoumei Bai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The basics of epithelial-mesenchymal transition

(2009) Raghu Kalluri et al.   JOURNAL OF CLINICAL INVESTIGATION

Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis

(2009) Souhila Medjkane et al.   NATURE CELL BIOLOGY

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma

(2009) R. C. Kane et al.   ONCOLOGIST

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

(2009) C. J. Creighton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Snail and Slug Mediate Radioresistance and Chemoresistance by Antagonizing p53-Mediated Apoptosis and Acquiring a Stem-Like Phenotype in Ovarian Cancer Cells

(2009) Nawneet K. Kurrey et al.   STEM CELLS

Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line

(2008) Jin Kyung Rho et al.   LUNG CANCER

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS